BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22658438)

  • 1. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene.
    De Langhe S; De Ruyck K; Ost P; Fonteyne V; Werbrouck J; De Meerleer G; De Neve W; Thierens H
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):393-9. PubMed ID: 22658438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Aizer AA; Anderson NS; Oh SC; Yu JB; McKeon AM; Decker RH; Peschel RE
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):379-84. PubMed ID: 20452135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
    Marchand V; Bourdin S; Charbonnel C; Rio E; Munos C; Campion L; Bonnaud-Antignac A; Lisbona A; Mahé MA; Supiot S
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1053-9. PubMed ID: 19880259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
    Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
    Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions.
    De Langhe S; De Meerleer G; De Ruyck K; Ost P; Fonteyne V; De Neve W; Thierens H
    Radiother Oncol; 2014 Jul; 112(1):95-9. PubMed ID: 24951017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.
    Fachal L; Gómez-Caamaño A; Peleteiro P; Carballo A; Calvo-Crespo P; Sánchez-García M; Lobato-Busto R; Carracedo A; Vega A
    Radiother Oncol; 2012 Dec; 105(3):321-8. PubMed ID: 23075580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S; Kannan V; Deshpande S; Anand V; Ghadi Y
    J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.
    De Meerleer G; Fonteyne V; Meersschout S; Van den Broecke C; Villeirs G; Lumen N; Ost P; Vandecasteele K; De Neve W
    Radiother Oncol; 2008 Nov; 89(2):205-13. PubMed ID: 18771809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.